ABCL News and Press, AbCellera Biologics Inc. From 02/21/23

The following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2022 Q4 earnings call. For further details see: AbCellera Biologics Inc. 2022 Q4 - Results - Earnings Call Presentation

AbCellera Biologics Inc. (ABCL) Q4 2022 Earnings Conference Call February 21, 2023 5:00 P.M. ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer, and President Andrew Booth - Chief Financial Officer ...

AbCellera Biologics press release ( NASDAQ: ABCL ): FY GAAP EPS of $0.50 misses by $0.09 . Revenue of $485.42M (+29.4% Y/Y) misses by $32.31M . For further details see: AbCellera Biologics GAAP EPS of $0.50 misses by $0.09, revenue of $485.42M misses by $32.31M

Total revenue of $485 million, compared to $375 million in FY 2021 Total cumulative partnered program starts of 101, with 23 new starts in the year Net earnings of $0.56 per share on a basic and $0.50 on a diluted basis, compared to earnings of $0.56 (basic) and $0.48 (diluted) pe...

AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be post...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...

AbCellera (Nasdaq: ABCL) will announce its full year 2022 financial results on Tuesday, February 21, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link tha...

AbCellera Biologics ( NASDAQ:ABCL ) is a Vancouver-based biotechnology company that develops an antibody discovery platform. Today, I want to discuss what lies ahead for this biotech stock in 2023 and beyond. Let’s jump in. How has this biotech stock performed over the past yea...

PTAB rejects third request by Berkeley Lights for invalidation of AbCellera’s U.S. patents AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter P...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...